MBT
VRTX icon

Monroe Bank & Trust’s Vertex Pharmaceuticals VRTX Stock Holding History

Monroe Bank & Trust’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-340
Closed -$37K – 285
2017
Q1 		$37K Buy
+340
New +$29.9K 0.01% 172
2016
Q2 		– Sell
-48
Closed -$4K – 313
2016
Q1 		$4K Buy
+48
New +$4.34K ﹤0.01% 337

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Monroe Bank & Trust's VRTX Position: Q2 2017 in Review

Monroe Bank & Trust sold out of Vertex Pharmaceuticals (VRTX) in Q2 2017, closing a stake of 340 shares — an estimated $37K sold.

Monroe Bank & Trust first reported a position in VRTX in Q1 2016 and held it in 2 quarters. The position peaked at $37K in Q1 2017. 582 funds tracked by Wall St. Rank hold VRTX as of Q2 2017.

  • Monroe Bank & Trust reported no remaining Vertex Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Monroe Bank & Trust sold 340 Vertex Pharmaceuticals shares in Q2 2017, an estimated $37K.
  • Monroe Bank & Trust first reported a position in Vertex Pharmaceuticals in Q1 2016 and held it in 2 quarters.
  • Monroe Bank & Trust's Vertex Pharmaceuticals position peaked at $37K in Q1 2017.
  • 582 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2017.

Based on Monroe Bank & Trust's 13F filing for Q2 2017, filed 8 Aug 2017.